Abstract In the present paper the development and application of a novel somatostatin radioimmunoassay are described.
Introduction
During our research we were investigating the distribution of two peptide hormones from the same peptide family, namely the somatostatin and the thrittene, in the rat central nervous system (CNS) with radioimmunoassay (RIA).
The somatostatin was discovered in 1973 by Brazeau et al. [1] as a peptide which potently inhibited growth hormone release from the anterior pituitary. Originally it was isolated from the hypothalamus, but thereafter was evinced in the CNS, gastrointestinal tract (GIT) and the pancreas with immunohistochemistry and RIA [2, 3] . Somatostatin has two biologically active form, the 28 and the 14 amino acids containing cyclic polypeptides (Table 1) , which are produced in the CNS, primarily in the hypothalamic neurons, furthermore in the D cells of the GIT and the pancreas [4] . From the coding gene, 116 amino acids containing, preprosomatostatin is synthesized. This primary precursor is cleaved to form pro-somatostatin, a further precursor consists of 92 amino acids [5] . This molecule undergoes proteolytic processing at the COOH terminus as well as at the HN 2 terminus. This C-terminal cleavage leads to the biologically active somatostatin-28 form, from which another enzymatic cleavage results in the somatostatin-14 [6] [7] [8] . From its discovery as an inhibitor, somatostatin is known to be a universal inhibitory substance with multiple actions: it may act as a hormone via the circulation, as a paracrine effector via local regulatory mechanisms, or as a neurotransmitter via synaptic junctions [9] .
Thrittene belongs also to the family of related peptides containing somatostatin and cortistatin (Table 1) . It was identified by Ensinck et al. [10] and the peptide was purified from monkey ileum. Its amino acid sequence, molecular mass and chromatographic characteristics conformed to those of somatostatin-28 (1-13), a peptide not describe heretofore. The peptide was detected in the GI tract of mammalians by immunohistochemistry, and then developed a subtraction RIA method to measure the peptide, and the help of this method defined the peptide concentration in different tissues and proved the peptide presence in the circulation. Later confirmed, that the release of the thrittene is the effect of dining and get into the circulation. The components of the food affect the releasing of the peptides (somatostatin and thrittene). If the food is rich in carbohydrates, it increases the concentration of the thrittene in the plasma, while the food is rich in proteins that will affect the releasing of the somatostatin-28 [11] . From the fact that the thrittene and the somatostatin-28 respond differently to the components of the food, furthermore the histological distribution of this two peptide is diverse, concluded that the synthesis of the two peptides is not related, therefore the coding gene of the preprosomatostatin does not play a part in the biosynthesis of the thrittene [10, 11] .
To confirm or confute the upper conclusion the research plane was designated to identify the somatostatin and thrittene concentrations in different rat brain areas with specific RIA methods, then define the somatostatin/ thrittene ratio in every brain part. If this ratio shows huge variation (so the ratio if this two peptide producing cells is different in the investigated brain areas) we can confirm the conclusion. In that case the ratio is spreading around an average, and then we need to confute the previous researches. Because this could be possible in that case, when the somatostatin and the thrittene concentration parallel change in different brain parts, then the ratio remains constant. But in that case we need to suppose the thrittene is mostly produced during synthesis of the somatostatin (but we can not exclude totally different biosynthetic pathways).
In the presented research study we investigated the distribution of two biological active peptides in the rat nervous system with radioimmunoassay. This micro analytical technique is a competitive protein binding method for the quantitative determination of antigenically active substances that are present in very small amounts, such as peptide hormones. The concentration of an unknown, nonlabelled antigen is determined by comparing its inhibitory effect on the binding of radioactively labelled antigen to a specific antibody with the inhibitory effects of known standards. The used direct specific thrittene RIA method was adjusted in 2012 in our laboratory [12] . But to measure the somatostatin we educed a new method. Our aim was to 125 I, free from reducing agent for protein iodination from Institute of Isotopes (Budapest, Hungary); sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride and dichloromethane from VWR International (Debrecen, Hungary); trifluoroacetic acid (TFA) from Fluka (Buchs, Switzerland); HPLC-grade acetonitrile from Carlo Erba (Rodano, Italy). Polypropylene RIA tubes (12 9 75 mm) were obtained from Merck (Darmstadt, Germany). The animals (New Zeeland white rabbits and Wistar rats) were purchased from Charles River Laboratories (Budapest, Hungary).
Description of thrittene radioimmunoassay
Thrittene RIA was performed in the study as previously described [12] . Briefly, the conditions were as follows: antisera of thrittene ''TH3/6'' was raised against a conjugate of thrittene and BSA coupled by glutaraldehyde in rabbit (dilution: 1:60,000); tracer: mono-125 I-labeled Tyr (0) -thrittene prepared in our laboratory (3000 cpm/tube); standard: synthetic thrittene ranging from 0 to 100 fmol/ml; buffer: assay prepared in 1 ml of 0.05 mol/l (pH 7.4) phosphate buffer containing 0.1 mol/l sodium chloride, 0.25% (w/v) BSA and 0.05% (w/v) sodium azide; incubation: 48 h at 4°C; separation solution: charcoal/dextran/milk powder (10:1:0.2 g in 100 ml of distilled water); centrifugation: 4000 rpm, 4°C, 10 min.
Development of somatostatin radioimmunoassay

Synthesis of somatostatin-14
Somatostatin-14: H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-TrpLys-Thr-Phe-Thr-Ser-Cys-OH (disulfide bridge: 3-14) was prepared applying t Boc chemistry. The peptide chain was elongated on a Pam resin (0.7 mmol/g) and the synthesis was carried out manually. The side-chain protecting groups were the followings: Boc-Lys(2ClZ), Boc-Cys(Meb) and BocThr(Bzl). Couplings were performed with DCC and HOBt, without difficulties. Amino acid incorporations were monitored by quantitative ninhydrin test [13] . The completed peptide resin (1 g) was treated with liquid HF/dimethyl sulphide/p-cresol/p-thiocresol (86:6:4:2 v/v), on 0°C, 45 min. HF (hydrogen fluoride) was removed and the resulted free peptide was solubilized in 10% aqueous acetic acid, filtered and lyophilized. The crude peptide (150 mg) was dissolved in distilled water (100 ml) and 3 ml of 0.1 mmol/l potassium hexaciano ferrate (III) was added under stirring. After 3 h the solution was lyophilised and purified by semipreparative RP-HPLC using a solvent system of (A) 0.1% TFA (trifluoroacetic acid) and (B) 80% acetonitrile on a Phenomenex Jupiter (Torrance, California, USA) C18 10 lm column (15 9 250 mm). The HPLC apparatus was made by Knauer (Berlin, Germany). Absorbance was detected at 220 nm. Purity of the cyclized peptide was evaluated by analytical RP-HPLC on a 4.6 9 250 mm Phenomenex Luna C18 column using a HP 1100 HPLC system made by Hewlett Packard (Palo Alto, California, USA). The optimal HPLC conditions for the analytical controls were: flow: 1.0 ml/min; gradient: 35-50% in 15 min.
Preparation of BSA-somatostatin-14 immunogen 10 mg purified cyclized peptide (H-Ala-Gly-Cys-Lys-AsnPhe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH, disulfide bridge between the 3-14 Cys), 10 mg BSA and 16 ll glutaraldehyde were dissolved in 4 ml of phosphate buffer (pH 7.8) at 4°C and was stirred for 12 h. The incorporation of peptide into conjugate was monitored by addition of a trace amount (10,000 cpm) of 125 I-labelled RIA tracer to the reaction mixture [39] . Dialysis was made against distilled water using dialysis tubing at 4°C for 48 h. The incorporation of label into conjugate was 73%. The obtained conjugation mixture (BSA-somatostatin-14 immunogen) was lyophilized and kept to be used for immunization.
Immunization
Approximately 800 lg BSA-somatostatin-14 conjugate was emulsified in 1 ml of emulsion of Freund's complete adjuvant and sterile saline (1:1) and injected intradermally, at 8-10 sites, into each of 5 young male New Zeeland white rabbits (weight: 2-2.2 kg). Further immunizations with the half of starting dose of conjugate (400 lg/ml per animal) were made at 5-week intervals [39] . Finally, the rabbits were bled from an ear vein 2 weeks after the 5th, last successive immunizations. The collected sera were stored at -80°C. The antisera were tested for titre and specificity by comparing the binding of several somatostatin-like peptides in RIA conditions.
Iodination of Tyr (0) -somatostatin-14
Freshly dissolved iodogen (10 lg) in dichloromethane (100 ll) was dispersed in the bottom of a polypropylene iodination vial and evaporated to dryness under nitrogen flow. Subsequently, 0.25 mol/l, pH 7.4 phosphate buffer (100 ll) and Tyr (0) -somatostatin-14 (20 nmol/40 ll) were added together with 18.5 MBq/5 ll carrier-free and free from reducing agent Na 125 I. The labeling process had been allowed to run for 4 min at room temperature. To terminate the iodogen mediated oxidizing reaction 0.1% (v/v) TFA (400 ll) was administered into the reaction tube. Immediately thereafter, the reaction mixture was loaded onto a reversed-phase HPLC column for separation.
Reversed-phase HPLC separation
Radio-labeled products of the iodogen labeling reaction were fractionated by means of reversed-phase HPLC technique. The HPLC system comprised a Merck-Hitachi pump (type: L-7100), a Rheodyne injector (type: 7161), a LiChrospher 100 RP-18 (5 lm, 4 9 250 mm) reversedphase column and a Merck fraction collector (type: L-7650). The column was washed with acetonitrile (solvent B), then equilibrated with 0.1% (v/v) TFA (solvent A) prior to use. HPLC-grade acetonitrile as an organic component along with aqueous solution of 0.1% (v/v) TFA was employed to elute the radio-labeled peptides and free 125 I -ion at a flow rate of 0.5 ml/min. Fractions at a volume of 0.5 ml were collected. Finally, the radioactivity of an aliquot volume (5 ll) of each fraction was determined in a gamma counter (Gamma NZ 310).
Identification of various radioactive products
Free iodine and mono-or di-iodinated forms of Tyr (0) -somatostatin-14 occurred as three distinct peaks after reversed-phase HPLC separation. Identification of the various products based on their order of appearance (free iodine occurring in the first peak) or binding to the raised somatostatin (SOM4/5) antibody (mono-or di-iodinated forms). Subsequently, determination of specific radioactivity of the radio-labeled peptides was performed by the self-displacement method described by Morris [14] to distinguish the mono-iodinated from the di-iodinated one.
Description of somatostatin radioimmunoassay
Antiserum SOM4/5 was raised against a conjugate of somatostatin-14 and BSA coupled by glutaraldehyde in a rabbit. Tracer Mono-125 I-labeled Tyr (0) -somatostatin-14 was prepared in our laboratory. Standard Somatostatin-14 was used as a RIA standard ranging from 0 to 200 fmol/ml. Buffer The assay was prepared in 1 ml 0.05 mol/l (pH 7.4) phosphate buffer containing 0.1 mol/l sodiumchloride, 0.25% (w/v) BSA and 0.05% (w/v) sodium azide. Assay procedure 100 ll antiserum (working dilution 1:3000), 100 ll RIA tracer (3000 cpm/tube) and 100 ll somatostatin-14 standard or unknown samples were measured into polypropylene tubes with the assay buffer. After 48 h incubation at 4°C, the antibody-bound peptide was separated from the free one by addition of 100 ll separating solution (10 g charcoal, 1 g dextran and 0.2 g commercial fat-free milk powder in 100 ml distilled water) [39] . Following centrifugation (4000 rpm, 4°C, 10 min) the tubes were gently decanted and the radioactivity of the precipitates was measured in a gamma counter (Gamma NZ310). Somatostatin-14 concentrations of the unknown samples were read from a calibration curve.
Every step of the RIA determination (preparation, incubation, separation) was carried out at low temperature, on ice or at 4°C. The optimal incubation time for this somatostatin RIA is 48-72 h at 4°C (Fig. 1) .
Animal tissue extraction
Overnight fasting male Wistar rats (250-300 g) were anaesthetized with 50 mg/kg i.p. pentobarbitone sodium (Nembutal), killed by cervical dislocation and exsanguinated. Thereafter, the whole brain was removed and the following five brain areas were separated and collected: telencephalon, mesencephalon, cerebellum, hypothalamus and medulla oblongata. The tissue samples were placed on ice, after cooling, cleaned, weighed and homogenized in ice-cold distilled water to give a 10% (w/v) homogenate. Finally the homogenates were centrifuged (10,000 rpm, 4°C, 30 min) and the supernatants were transferred for somatostatin and thrittene radioimmunoassay measurements. Content of peptides of various brain areas were expressed as fmol/mg wet tissue weight. Data are expressed as mean ± standard error of means (SEM).
Ethics
The experimental protocols applied in the present work conformed to the European Community guiding principles for the care and use of laboratory animals and were approved by the Local Ethical Committee of the University of Debrecen, Hungary.
Results
Synthesis of somatostatin-14
The lyophylisation of the pooled fractions led to 38.1 mg of pure somatostatin-14, resulting 25.4% overall yield. Analytical RP-HPLC: Phenomenex Luna (4.6 9 250 mm) C18 column; flow: 1.0 ml/min; acetonitrile gradient: 35-50% in 15 min; retention time: 7.18 min; mass spectrometry: measured molecular weigh: 1637.4, calculated: 1637.89. (The synthetic peptide was characterized by mass spectrometry using a Finnigan TSQ 7000 tandem quadrupol mass spectrometer equipped with electrospray ion source.) The pure peptide was used as RIA standard and for immunization in conjugated form. (Fig. 2) . 
Characterization of antiserums
The raised somatostatin antiserums were tested for titre and specificity by comparing the binding of several somatostatin-like peptides.
The titre values of the somatostatin antiserums were determined in assay conditions. The titre dilutions were as follows: SOM1/5 1:8000; SOM2/5 1:17,000; SOM3/5 1:5000; SOM4/5 1:30,000; SOM5/5 1:23,000. Antiserum (SOM4/5) with the highest titre proved to be most successful for the development of RIA. This somatostatin antiserum, raised against a conjugate of BSA and somatostatin-14 turned to be C-terminal specific based on cross-reaction studies ( Table 2) .
Somatostatin radioimmunoassay characteristics
The average ID 50 value (i.e. the concentration of RIA standard (somatostatin -14) , that displaces 50% of the tracer from the antibody) was 15.18 ± 2.02 fmol/ml as determined in ten consecutive assays (Fig. 3) .
Sensitivity
Sensitivity of an assay is the minimum detectable concentration (detection limit) of the antigen. The detection limit of our somatostatin RIA was calculated from a decrease in binding of two standard deviations in the mean of zero standard of ten replicates [40] . This value was 0.24 fmol/ ml. The lowest level of somatostatin-14 that can be detected by this assay is approximately 0.2 fmol/ml.
Precision
Intra-assay precision (within assay variation) and inter-assay precision (between assay variation) was performed on three pooled samples containing varying concentrations (low, medium, high) of somatostatin-14. The measured concentrations of somatostatin-14 of the samples and the calculated data are presented in Table 3 . Shown data are from ten duplicate determinations for within assay variation and ten consecutive duplicate determination for between assay variation.
Somatostatin and thrittene contents of brain samples
Somatostatin immunoreactivity was present in the examined brain areas of rat with highest concentrations in the cerebellum followed by telencephalon, mesencephalon, hypothalamus and medulla oblongata. The thrittene immunoreactivity in the different brain parts showed a very similar tendency. The highest thrittene concentration was measured in the cerebellum, lowest in the medulla oblongata. The somatostatin concentration in every investigated tissue sample was approximately fivefold higher than the determined thrittene content in the same brain area (Fig. 4) . 
Discussion
The present study provided a description of a highly sensitive and specific radioimmunoassay method to measure a peptide called somatostatin in the radio-analytical laboratory of our department. The objective of the present work was to develop a method, which can measure both of the biologically active forms of somatostatin (somatostatin-28 and 14) in the biological samples. The only way it was possible, if in the RIA used antibodies recognize and bind to the common C-terminals of the peptides. For this purpose glutaraldehyde coupling was used in this study to create the immunogen, due to the fact that this fixation method crosses the peptide through the N-terminal end to the carrier peptide (BSA). Consequently, the C-terminal part of the peptide remained free so the generated antibodies (mainly IgG) were produced against this sequence hence the antibody recognizes the common C-terminal region of somatostatin-28 and 14. In the cross-reaction examination of our new ''SOM4/5'' antiserum we found a limited binding (5-10%) to the rat and human cortistatin peptides (Table 1) but the values of these bindings are not important, so the antibody recognizes and binds mainly somatostatin-28 and 14. 125 I is the most commonly used isotope for labeling of peptide hormones in order to perform RIA measurements. The widely applied oxidizing agents are: chloramine-T [15] [16] [17] [18] [19] [20] [21] [22] [23] 40] , hydrogen peroxide [24] and iodogen [12, 16, [25] [26] [27] [28] [29] [30] [31] 39] . After the labeling procedure the mono-iodinated Tyr (0) -somatostatin-14, serving later as RIA tracer, must be separated from the other compounds (di-iodinated Tyr (0) -somatostatin-14, unlabelled peptide, unincorporated iodine, oxidatively damaged labeled or unlabelled products). The present work provides a description of iodination, using iodogen, a solid-phase oxidizing agent, and separation by reversed-phase HPLC of Tyr (0) -somatostatin-14. High purity of the mono-125 I-labelled Tyr (0) -somatostatin-14, as a RIA tracer, is of crucial importance to carry out reliable measurements. Accordingly, the purpose of various iodination and separation procedures (gel filtration [16, 21, 23, 30, 32, 40] , starch gel electrophoresis [33] , paper electrophoresis [15, 20] , thin layer chromatography [25, 28] , ion-exchange chromatography [19, 34] , reversed-phase HPLC [12, 15, 17, 22, 29, 31, [35] [36] [37] 39] ) is to achieve the highest yield and purity of mono-iodinated form. Under optimal labeling and purification conditions as described above, the fraction of the mono-iodinated form can be as high as 70-75%. The specific radioactivity values of the mono-and di-iodinated forms of Tyr (0) -somatostatin-14 are nearly identical with the theoretical values (78.63 and 157.26 TBq/mmol) [38] , documenting high efficacy of the reversed-phase HPLC separation technique employed. To prepare the optimal RIA tracer, the radioactive labeling must be as far as possible from the binding region. This problem was solved by coupling a Tyr amino acid, which is essential for the iodination, in zero position to the N-terminal region of somatostatin-14. Incorporation of iodine into a peptide can modify the structure of the molecule, and if this modification is at the binding region, it can change the binding property or can extinguish it. In our case there was no such problem as the C-terminal part is recognized by the antibody, the radioactive labeling was performed at the zero position of the N-terminal region.
As a practical application of the novel RIA, in this study the somatostatin concentration was measured parallel with the determination of thrittene content in different rat brain areas. The highest somatostatin concentrations were detected in the cerebellum followed by telencephalon, mesencephalon, hypothalamus and medulla oblongata. The thrittene immunoreactivity in the same brain parts showed a similar tendency. It is striking that in all cases the ratio of the two peptides are almost the same, namely the amount of the somatostatin measured in the same samples is about 5 times the thrittene concentration. (Our work group has found similar results in a previous project, when comparing the somatostatin and thrittene concentration of specific intestinal regions.) These results verify our following theory: thrittene is not created via a specific biosynthetical route, but from the pre-prosomatostatin, and is one of its split products. If it was created in a different way, then in our opinion at least in some organs the ratio of the two peptides would be different. In our future experiments concerning digesting we will try to exactly prove (or peremptorily rule out) that thrittene is the degradation product of the S-28. According to our hypothesis the peptide is made when the 28-amino acid somatostatin splits, and from the C terminal region the S-14 forms (also with full biological activity). The remaining N terminal region contains the structure of the thrittene, however, one additional amino acid (Lys) has to be split off beforehand. During the experiment we will incubate native somatostatin-28 at 37°C in homogenisation of different organs for different amounts of time, giving the peptidase enzymes opportunity to split the S-28, and the peptides created during this process. After this, as the first step, using specific RIA methods, we will measure the thrittene and somatostatin concentrations of the organ media. If the thrittene amount in the incubated samples exceeds the basic amount, or if this shows a growing tendency during the incubation time, this will be an evidence for the biosynthesis of the thrittene. Of course, the peptides created during the incubation will be analyzed and identified. Methods for these may be HPLC separation and then amino acid analysis.
